Anca Askanase, MD
Enriched profileChair of the Department of Medicine and Chief of the Division of Rheumatology (effective April 2026) · Hospital for Special Surgery (HSS)
Anca Askanase is Chair of the Department of Medicine and Chief of the Division of Rheumatology (effective April 2026) at Hospital for Special Surgery (HSS). OpenAlex indexes 314 publications with 11,599 citations (h-index 49); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Anca D. Askanase, MD, is Chair of the Department of Medicine and Chief of the Division of Rheumatology (effective April 2026) at Hospital for Special Surgery (HSS), New York, NY. The public record shows 314 publications with 11,599 citations (h-index 49), centered on Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 18 companies.
- Most recent indexed publication: 2026 · Arthritis & rheumatology (Hoboken, N.J.)
- Top research focus: Systemic Lupus Erythematosus Research
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 54 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 134.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Sponsor: Hospital for Special Surgery, New York
- VIBRANT: VIB4920 for Active Lupus Nephritis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
Sponsor: Oklahoma Medical Research Foundation
Industry payments
Updated 27 Aug 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20257 payments$12,916openpaymentsdata.cms.gov ↗
- Genentech, Inc.Program year20254 payments
- Mylan Inc.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
39%Antimalarial39%Hydroxychloroquine Sulfate100%Part D≥19 patientsCancer & immunology
25.6%Nonsteroidal Anti-inflammatory Drug11.6%Celecoxib100%Part D<11 patientsFolate Analog Metabolic Inhibitor7.3%Methotrexate100%Part D<11 patientsNervous system
11%gamma-Aminobutyric Acid A Receptor Positive Modulator11%Zolpidem Tartrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
1 congress contribution (2024) across ASH per OpenAlex. The most recent:
- A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with Systemic Lupus Erythematosus
ASH Annual Meeting
ASH2024Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.
Arthritis & rheumatology (Hoboken, N.J.)
Guideline2026 - A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development.
Arthritis care & research
Article2026 - 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.
Arthritis care & research
Guideline2026 - Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study.
Rheumatology (Oxford, England)
Article2026 - Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
Arthritis & rheumatology (Hoboken, N.J.)
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Trial of Anifrolumab in Active Systemic Lupus Erythematosus1,337 citations2019
- 02Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus1,165 citations2005
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/anca-askanase-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/anca-askanase-a7bba684
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Anca-Askanase
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
lupus.org/resources/the-expert-series-bonus-episode-the-awakening-when-lupus-looks-like-mental-illness
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile: "Anca Askanase - Professor of Medicine at Columbia" (linkedin.com/in/anca-askanase-a7bba684), auth-walled, corroborated via SERP snippet
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board Certified
American Board of Internal Medicine (ABIM) - Rheumatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Leadership positions with American College of Rheumatology
Lupus Foundation of America, Lupus Research Alliance …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.hss.edu ↗ - Featured leadership profile
Lupus Foundation of America
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗ - Full member
Systemic Lupus International Collaborating Clinics (SLICC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →superdoctors.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatologyatcolumbia.org ↗
- Founder and Director
Columbia University Lupus Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗ - Associate Chair for Clinical Trials / Director of Rheumatology Clinical Trials
Columbia Division of Rheumatology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatologyatcolumbia.org ↗
Media & interviews
press, podcasts and appearances- PeerView CME video podcast
"Anca D. Askanase, MD, MPH / Philip J. Mease, MD, MACR" (with Philip Mease, on SLE management)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupusbmj.podbean.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University